Compare KREF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | CLLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 384.3M |
| IPO Year | N/A | 2014 |
| Metric | KREF | CLLS |
|---|---|---|
| Price | $6.64 | $4.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.58 | $8.33 |
| AVG Volume (30 Days) | ★ 1.3M | 37.9K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $545.92 | N/A |
| Revenue Next Year | N/A | $0.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.87 | $1.33 |
| 52 Week High | $9.98 | $5.48 |
| Indicator | KREF | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 61.93 |
| Support Level | $6.64 | $3.93 |
| Resistance Level | $7.50 | $4.46 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 96.27 | 68.59 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.